Interferon-a (IFN-a) induces cytogenetic responses of variable degree in patients with chronic myelogenous leukemia (CML). We sought t o establish the relationship between BCR-ABL transcript numbers measured by competitive 2-step reverse transcription polymerase chain reaction (RT-PCR) and cytogenetic status in CML patients treated with IFN-a. A total of 250 peripheral blood and 55 bone marrow samples from 127 Philadelphia chromosome positive (Ph') and 6 Ph-IBCR-ABL' CML patients were investigated. Twenty-one patients were studied at diagnosis and 112 on treatment. Of the 106 Ph+ patients treated with IFN-a, 24 had a complete cytogenetic response, 21 a partial response, 12 a minor response, 26 no response, and 23 were unknown. Using nested RT-PCR, all 305 samples were positive for BCR-ABL transcripts. To standardize results for variability in RNA and cDNA quantity and quality, w e quantified total ABL transcripts in each sample as internal control. The validity of ABL as internal control was shown by comparison with glu-HRONIC MYELOGENOUS leukemia (CML) is characterized in 90% to 95% of cases by the Philadelphia (Ph) translocation, t(9;22)(q34;qll). The juxtaposition of 3' sequences of the ABL gene from chromosome 9 and 5' sequences of the BCR gene on chromosome 22 results in a novel chimeric BCR-ABL gene, which plays a causal role in the pathogenesis of the disease.' The vast majority of CML patients have breakpoints that result in a fusion mRNA in which either BCR exon b2 or b3 is fused to ABL exon a2 (b2a2 or b3a2 transcripts). Both transcripts give rise to a 2 10-kD BCR-ABL protein.
HRONIC MYELOGENOUS leukemia (CML) is char-
acterized in 90% to 95% of cases by the Philadelphia (Ph) translocation, t(9;22)(q34;qll). The juxtaposition of 3' sequences of the ABL gene from chromosome 9 and 5' sequences of the BCR gene on chromosome 22 results in a novel chimeric BCR-ABL gene, which plays a causal role in the pathogenesis of the disease.' The vast majority of CML patients have breakpoints that result in a fusion mRNA in which either BCR exon b2 or b3 is fused to ABL exon a2 (b2a2 or b3a2 transcripts). Both transcripts give rise to a 2 10-kD BCR-ABL protein.
Interferon-a (IFN-a) induces hematologic remission in about 60% to 80% of CML patients in chronic In most studies, patients on IFN-a who obtain major chromosomal responses survive significantly longer than those who do not?" It has been suggested that the tumor burden on therapy, ie, the residual amount of leukemia-specific Ph' cells in the body after treatment, corresponds with ~urvival.~
The standard method to estimate the tumor burden in CML patients is cytogenetic analysis of bone marrow (BM) aspirates. However, this method is limited by requirement for dividing cells and is not applicable to patients who have Ph-BCR-ABL+ disease. The hybrid BCR-ABL gene is leukemia-specific and can be used as a marker to identify and quantify residual disease on treatment. At the DNA level, the specific rearrangement of the major breakpoint cluster region (M-bcr) of the BCR gene can be monitored by quantitative Southern Fluorescence in situ hybridization (FISH) can be used to detect and quantify the BCR-ABL rearrangement in interphase cells,'0*'' and the fusion protein can be detected directly and quantified by Western blotting." Levels of residual disease in CML patients after allogeneic BM transplantation (Bh4T) have been monitored by quantitative reverse transcription-polymerase chain reaction (RT-PCR).'3.'4 Increasing numbers of BCR-ABL transcripts can be cosed-phosphate dehydrogenase transcript levels in 145 samples. The median BCR-ABL transcript numbers (and BCR-ABLIABL ratios expressed as percentages) were 4001 p g RNA 10.04%) in complete responders, 20,500lpg RNA (7.1%) in partial responders, 17O,OOO/pg RNA (21.0%) in minor responders, and 430,OOOlpg RNA (58.7%) in nonresponders (P .001). The cytogenetic results correlated with the BCR-ABL transcript numbers ( r = .82; P c .001) and BCR-ABLIABL ratios ( r = .84; P < .001). Grouping the ratios BCR-ABLIABL as less than 2%, 2% t o 14%, and greater than 14% t o compare with Cytogenetic complete response, partial response, and minorlnonresponse, the concordance between the two methods was 82% (2 P < .OOOl). We conclude that quantitative PCR with internal controls is a sensitive and reliable method for monitoring patients on IFN-a and reduces the need for repeated marrow investigations. detected on analysis of sequential peripheral blood (PB) specimens in patients who subsequently relapse. In this report, we have evaluated quantitative PCR as a method to monitor the response of CML patients to therapy with IFN-a.
MATERIALS AND METHODS

Patients.
A total of 133 patients (83 male and 50 female; median age at diagnosis, 44.9 years; range, 10.4 to 83.4) with CML in first chronic phase were studied prospectively. Informed consent was obtained as required by the Declaration of Helsinki. Twenty-one patients were investigated at diagnosis, 112 on or after treatment with IFN-a-based therapies. At the time of RT-PCR analysis, patients had received 2 to l10 months (median, 26) of treatment with recombinant IFN-a2a, b, or c, or lymphoblastoid IFN-anl. Seventynine patients received one or more additional therapies: hydroxyurea (n = 73), busulfan (n = 6), cytosine arabinoside (n = 3), thioguanine (n = l), mercaptopurine (n = l), and combination chemotherapy (ICE protocol: idarubicin, cytosine arabinoside, etoposide; n = 3).
One patient had had a splenectomy, and in one case the spleen had been irradiated. In 9 patients, an autologous BMT or stem cell transplantation had been performed. The hematologic response was defined as described. ' Cytogenetic onolwis. Cytogenetic studies were performed on BM aspirates according to standard protocols. Metaphases from direct and/or short-term (24-hour or 48-hour) cultures were examined after Giemsa banding." The cytogenetic response was evaluated according to Kantarjian et a17: complete response, 0% Ph' metaphases: partial response. l % to 34% Ph' metaphases: minor response, 3S% to 94% Ph' metaphases; and nonresponse. greater than 94% Ph' metaphases. Between 4 and 1 0 0 (median. 30) metaphases were analyzed. A total of 172 PCR results were available for comparison with contemporaneous cytogenetic analysis. Of these 172 results, 80 specimens were obtained on the same day for quantitative PCR and cytogenetic analysis. An additional 92 PCR results were obtained at intervals of up to 3 months from cytogenetic analysis in patients who continued IFN-n treatment and who had no change in hematologic response status.
Qlrcrlitutivr and q~rccntircrti~v PCR. Total leukocyte RNA was extracted from 10 to 20 mL of PB and/or from I to S mL of BM aspirate after lysis of red blood cells.'" Samples were received either locally or by mail and spent between 1 to 4 days in transit. Conditions for RNA extraction, reverse transcription, and two-step (nested) PCR for BCR-ABL have been described."' An estimate of the number of BCR-ABL transcripts was made in all specimens using a competitive PCR titration assay.'' We have previously shown in CML patients after allogeneic BMT that this assay gives reproducible results (coefficient of variation, 0.17)." Ela2 (~190) BCR-ABL transcripts were monitored in I patient using the primers and the competitor constntct for pl90-BCR-ABL.I7 Total ABL mRNA was quantified in all samples as an internal standard using the p210 competitor construct but different oligonucleotide primer^.'^ Total ABL is the result of the amplification of both normal ABL and BCR-ABL transcripts. As a second internal standard, glucose-6-phosphate-dehydrogenase (G6PD) transcripts were quantitied in a single-step PCR by using the primers G6PD-I (S'CCGCATCGACCACTACCTGGGCAA-G3'. exon 6 ) and G6PD-2 (S'GTTCCCCACGTACTGGCCCAGG-ACCA3'. exon 9).
The competitor construct used for G6PD-quantification was constructed using plasmid pGdBBX. a full-length G6PD cDNA in the vector P U C I~. '~ This plasmid was digested with NCO 1, which cuts at a single site in exon 8. After filling in the sticky ends.''' fragments of bacteriophage A DNA that had been digested with Alrc I were cloned into the cut site. After transformation into Escherichicc coli strain DHS. a single clone. designated pG6PDcompS. that harbored a A insert of approximately 100 bp was selected. pG6PDcompS is 4.6 kb in size: therefore. I ng equals 2.07 X 10" molecules.'" After linearization with RnnrHl serial dilutions of the plasmid were prepared in 1 rnmol/L Tris (pH 8.0). 0.1 mmol/L EDTA. S0 pg/mL E coli tRNA as described."
The equivalence point between different competitor concentrations was determined by densitometric analysis (UVP Gel Documentation System 5000: Ultra Violet Products. Cambridge, UK) of the ethidium bromide gels. Strict precautions were taken to prevent contamination of samples. and all experiments included negative controls I' rom a11 stages of the reactions.
Sorrthern blot oncclysis. Southern blotting was performed as reported.'" DNA obtained from PB or BM was digested with Hindlll. EcoRI, and R,?/ 11. was electrophoresed on a 0.7% agarose gel. was blotted. and was hybridized to 2-kb BgI IllHindlll (S"-bcr) and I .2-kb HindllI/R,ql II (3'M-bcr) probes.
Stotisticol methocls. PCR results were expressed as the number of BCR-ABL, ABL, and G6PD transcripts per microgram of RNA and as the ratios between BCR-ABL and ABL and between BCR-ABL and G6PD transcripts, expressed as percentage. BCR-ABL transcript numbers and BCR-ABLIABL ratios were compared with the proportion of Ph' metaphases for all samples that had contemporaneous cytogenetic analysis. The correlation between the percentage of Ph' metaphases and levels of BCR-ABL transcripts and BCRABLlABL ratios was evaluated using Spearman's rank correlation coefficient. The comparison of the BCR-ABL transcripts and BCR-ABUABL and BCR-ABLlG6PD ratios between the cytogenetic response groups was made using the Kruskal-Wallis test. the Mann- 
RESULTS
Qualitative PCR. A total of 305 (250 PB and 55 BM) samples from 133 CML patients were analyzed by RT-PCR for BCR-ABL transcripts. Between 1 and 1 1 (median, 2) samples were investigated from each patient during followup periods of up to 33 months. All samples were BCR-ABL'; 58 patients (44%) had b2a2 transcripts, 55 patients (41 %) had b3a2 transcripts. I8 patients ( 13%) had both b2a2 and b3a2 transcripts, I patient (1%) had b3a3 transcripts, and I patient ( 1 %) had el a2 transcripts. There was no difference in the distribution of b2a2 and b3a2 transcripts between the different cytogenetic response groups. (n = 24), partial (n = 21), minor (n = 12), or none (n = 26). Twenty-three patients on IFN-a either did not have cytogenetic investigation or the analysis failed.
Comparison of quantitative PCR and cytogenetics. The BCR-ABL transcript levels of all samples investigated ranged between 10 and 1,600,000/pg RNA (median, 60,000). Total ABL transcripts were quantified as internal standard in all samples and found to be between 310 and 5,700,000/pg RNA (median, 540,000; see Fig 1) . The BCR-ABL transcript numbers correlated with the percentage of Ph+ metaphases in those samples that had contemporaneous karyotypes (n = 172; r = 32, P < .001). The correlation between the ratio of BCR-ABUABL and the percentage of Ph+ metaphases was r = .85 and P < . OO1 (Fig 2) . If only samples that had at least 1 Ph+ metaphase were considered (n = 128), the BCR-ABL transcript numbers ( r = .65, P < .OOl) and the ratios BCR-ABUABL ( r = .67, P < .OOl) still correlated with the Ph status. The correlation was similar using only cytogenetic results with 20 or more metaphases analyzed (Table 1) .
Cytogenetic response to IFN-a (complete, partial, or minorhone) was compared with molecular response by introducing cutoff points in the BCR-ABUABL ratio. Using empirically derived optimum cutoff points of 2% and 14% (ie, comparing a ratio <2% with complete cytogenetic responders, between 2% to 14% with partial cytogenetic responders, and >14% with minor and nonresponders), 141 of 172 (82%) of samples were concordant between the two methods (x2 P < .0001; see Table 2 ). If only samples that had at least 20 metaphases analyzed are considered, then 11 2 of 135 (83%) were concordant. The number of BCR-ABL transcripts and the ratio of BCR-AJ3UABL differed significantly between the four cytogenetically defined response groups ( P < .OOl). However, there was no difference between patients at diagnosis and nonresponders to IFN-a (Table 3 and Fig 3) . Of the 53 samples from cytogenetic nonresponders, 18 were obtained when there was a complete hematologic response, 25 during partial hematologic response, and 10 when there was no hematologic response. The BCR-ABL transcript numbers and ratios BCR-ABUABL are not significantly different between these hematologic response groups. BCR-ABL levels in PB and BM. In 19 cases, PB and BM samples obtained on the same day were available for comparison. The BCR-ABL transcript numbers in the two tissues were not significantly different ( P = .34), although there was a trend towards a higher BCR-ABUABL ratio in the BM ( P = .OS). The log of the ratios BCR-ABUABL correlated well between PB and BM samples ( r = .98, P < .001; see Fig 4) .
Ph-patients. A total of 22 samples from 6 Ph-CML patients were investigated. All patients showed an M-bcr rearrangement at diagnosis by Southern blot analysis. In l patient, the rearranged M-bcr band disappeared on IFN-a therapy (complete Southern blot response). However, nested PCR was positive for BCR-ABL transcripts in all follow-up samples. The BCR-ABL transcript numbers of all samples from Ph-patients ranged between 20 and 1,200,0001pg RNA (median, 18,OOO) and the ratios of BCR-ABUABL ranged between 0.024% and 87% (median, 29%).
G6PD-quantijication. In 145 consecutive samples, G6PD transcripts were quantified as a second internal standard. The number of G6PD transcripts was at a median of 3.3 (range, 0.2 to 21.3) times higher than the number of ABL transcripts. G6PD and ABL transcript numbers correlated with r = .70 ( P < .001; see Fig 5) . The ratios of BCR-ABUG6PD correlated with the cytogenetic detection of the Ph-chromosome (n = 106; r = 22, P < .001; see Table 1 ).
A significant difference in the BCR-ABUG6PD ratio was found between the four cytogenetic response groups ( P < .OOOl). Introducing cutoff points of 0.3% and 5%, the concordance between molecular response and cytogenetic response groups was 83% ( P < .001).
DISCUSSION
The response of CML patients to IFN-a is an important prognostic indicator. In addition to hematologic parameters, assessment of the proportion of BM metaphases lacking a Ph chromosome is the standard technique for defining patient response. However, this technique does suffer from some limitations. For a significant proportion of patients undergoing treatment with IFN-a the BM is inaspirable. In some patients, only a small number of metaphases are evaluable, leading to a large statistical error in assignment of individuals to specific response groups. Also, approximately 5% of BCR-ABL+ patients have no cytogenetic abnormalities. As an alternative to cytogenetic analysis, patient response has been gauged by either quantitative Southern blotting,',' FISH,"." or Western blotting.12 These three techniques may be performed on PB samples and are applicable to all BCR-ABL' CML patients. In this report, we have shown that competitive RT-PCR to quantify BCR-ABL transcripts in PB specimens may also be used to monitor patient response to IFN-a. The sensitivity of quantitative PCR is considerably higher than that of other methods. The assay described is applicable to patients with different transcript types, and quantification of samples with both b2a2 and b3a2 transcripts is possible in the same reaction. Also patients with atypical BCR-ABL transcripts, eg, b3a3, can be monitored by this technique. For quantification of ela2 transcripts, which are found very rarely in CML," a different competitor construct and different primer sets have to be used. In combination with quantification of normal genes, the method is applicable even if the sample quality is variable.
Overall, we have found a good correlation between the cytogenetic detection of the Ph chromosome and BCR-ABL transcript levels, which is similar to results obtained in CML patients after allogeneic BMT.22 Furthermore, we found a significant difference in the number of BCR-ABL transcripts per microgram of RNA and the ratios of BCR-ABWABL between the four cytogenetic response groups. However, an exact correspondence between the two methods was not found. Possible reasons for the discrepances are twofold. First, the reproducibility of cytogenetic data depends on the number of metaphases analyzed.23 Importantly, in some IFNa-treated patients the availability of metaphases is restricted. Second, the two methods analyze different cell populations. Cytogenetic analysis examines myeloid cells in mitosis, selected according to the culture conditions. Competitive PCR measures amounts of BCR-ABL mRNA in total PB leukocytes including Ph-lymphoid cells. The sensitivity of quantitative nested PCR showed that patients who achieve complete cytogenetic responses have levels of BCR-ABL mRNA that may differ by as much as 10,OOO-fold.N The prognosis for patients with lower levels of residual disease may be better, but long-term follow-up will be necessary to discover if subclassification of complete cytogenetic responders by numbers of BCR-ABL transcripts has prognostic value. There was no correlation between the type of the BCR-ABL transcript and either cytogenetic or molecular response.
We found concordant quantitative PCR results in samples obtained from BM as compared with samples from PB. Similar results have been obtained by PCR in patients after allogeneic BMT'4,25 and by quantitative Southern blotting in patients treated with IFN-cY.~ Thus, CML patients can be monitored using PB samples rather than BM, permitting more frequent and less invasive analyses.
Routine quantification of a control gene product in patient samples enabled standardization of the BCR-ABL transcript levels. We used quantification of the ABL gene to control for possible variation in the quantity and quality of blood, RNA, and cDNA samples. The advantage of using ABL is that the same competitor construct used to quantify BCR-ABL may be used. We tested the validity of the ABL quanti- fication by comparing ABL and G6PD mRNA levels in samples of different qualities and different levels of BCR-ABL. The levels of ABL and G6PD were significantly correlated and similar results were obtained when either the BCR-ABL/ ABL or the BCR-ABUG6PD ratios were compared with cytogenetic results. This suggests that either gene may be used as an internal standard. The quantification of internal standards is of particular importance for multicenter studies because of the degradation of RNA during mailing but is also useful to control for variables in routine competitive PCR analysis.
In conclusion, competitive PCR is a useful tool to monitor Ph+ and Ph-/BCR-ABL+ CML patients on IFN-a therapy. The method is applicable for multicenter trials, allows a more frequent follow-up of the patients, and avoids the difficulties of cytogenetics in IFN-a-treated patient^."^.*^ For patients with stable transcript levels, quantitative PCR reduces the need for repeated BM aspirations. However, for patients who show a significant (eg, l-log) decrease or increase in BCR-ABL transcripts, cytogenetic or other investigations may be warranted. The combination of cytogenetics and molecular methods may significantly improve the ability to assess response in IFN-a-treated patients.
